A bibliometric analysis of publications on venous thromboembolism in children from 1988 to 2019

Lingyun Tian, MN\textsuperscript{a,b}, Ying Zhang, MN\textsuperscript{c}, Jiaqi Zeng, BN\textsuperscript{a}, Lijian Wang, BN\textsuperscript{a}, Huimin Gao, BN\textsuperscript{a}, Yayan Su, BN\textsuperscript{a}, Yinglan Li, PhD\textsuperscript{a,d,*}

Abstract

Introduction: Venous thromboembolism (VTE) in children not only imposes a heavy burden on the medical resources and economy of the society, but also seriously affects the growth and development of children, even threaten children’s lives. A large number of publications have been performed in this field in recent years. In this bibliometric analysis, publications on VTE in children were examined and analyzed to explain the present research hotspots.

Methods: Articles related to VTE in children published in the PubMed database from 1988 to June 18, 2019 were selected as the research sample. BICOMB software was used to retrieve the annual publications, journals, journal source countries and the high-frequency major medical subject headings (MeSH) terms on the articles. Then, the co-word matrix was constructed by BICOMB using the selected high-frequency MeSH terms. Next, gCLUTO software was used to analyze the matrix by double clustering and visual analysis in a strategy of hotspot identification. In addition, CiteSpace software was used to perform the knowledge map of co-authors to explore the core authors.

Results: One thousand seven hundred seventy-nine articles on VTE in children were obtained. Seven hundred ninety academic journals distributed in 58 countries have published articles on VTE in children, and the developed countries and the United States were the major force in the journal source countries. Nowak-Güttl U occupied an important position in this field. We constructed a co-word matrix composing of 37 high-frequency MeSH terms, generated visual matrix and visual hill, and classified the hot-spots into 5 aspects based on 8 categories.

Conclusion: The results show that the research trend of children’s VTE has been increasing gradually, and the sound achievement has been obtained in these hotspots in relation to the area of inherited thrombophilia, prevention and control, treatment, diagnosis, prevalence, risk factors, and complication study. However, there is a lack of communication and cooperation in this field, and the gap of national and regional research results is huge. To sum up, this study provides evidence and guidance for researchers, clinicians, and educators.

Abbreviations: ACCP = American College of Chest Physicians, BICOMB = Bibliographic Item Co-Occurrence Matrix Builder, CVAD = central venous access device, CVC = central venous catheter, DVT = deep venous thrombosis, ICU = Intensive Care Unit, IF = impact factor, IPC = intermittent pneumatic compression, IT = inherited thrombophilia, LMWH = low molecular weight Heparin, LOS = length of stay, MeSH = major medical subject headings, MJI = Manco Johnson Instrument, MRV = magnetic resonance Venography, MV score = modified Villalta score, PE = pulmonary embolism, PTS = post-thrombotic syndrome, RAM = risk assessment model, VTE = venous thromboembolism.

Keywords: bibliometric analysis, children, venous thromboembolic diseases, VTE

Editor: Vasile Valeriu Lupu.

This study was supported by the Hospital Management Research Fund of Xiangya Hospital, Central South University (No. 2016GL08), the Xiangya clinical big data system construction project of Central South University (No. 2013098) and Chinese Nursing Association (No. ZHKY201606).

The authors have no conflicts of interest to disclose.

Ethics approval and consent to participate: Not applicable.

Data availability statement: Data will be made available on request.

Correspondence: Yinglan Li, Xiangya School of Nursing, Central South University, Changsha, China; Department of Nursing, Xiangya Hospital, Central South University, Changsha, China.

Copyright © 2020 the Author(s). Published by Wolters Kluwer Health, Inc. This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildwork provided it is properly cited. The work cannot be used commercially without permission from the journal.

How to cite this article: Tian L, Zhang Y, Zeng J, Wang L, Gao H, Su Y, Li Y: A bibliometric analysis of publications on venous thromboembolism in children from 1988 to 2019. Medicine 2020;99:20(e20114). Received: 6 September 2019 / Received in final form: 25 January 2020 / Accepted: 3 April 2020 http://dx.doi.org/10.1097/MD.0000000000020114
1. Introduction
Venous thromboembolism (VTE), including pulmonary embolism (PE) and deep vein thrombosis (DVT), has been increased significantly over the past 20 years in children. A multicenter study conducted in the United States from 2001 to 2007 showed that the diagnostic rate of VTE in children increased by 70%, that is, 58 out of 10,000 hospitalized children (0.58%) had VTE.[2] This increase may be due to the advance in VTE diagnosis, successful medical or surgical interventions in childhood diseases such as premature infants, malignant neoplasms and congenital heart disease and the increasing use of central venous access device (CVAD).[3-5]

VTE in pediatric patients has a serious impact in terms of economic burden and disease progression. A child’s VTE can cost nearly $30,000, increase the average length of hospital stay by about 8 days, and increase the number of outpatient follow-up visits.[6-8] At the same time, 50% of children with VTE had no thrombus subsidence, the recurrence rate of VTE was 8%, and more than one third of children with VTE had the complication of post-thrombotic syndrome (PTS). The mortality rate of VTE in children was 2%, and even in pediatric patients with PE, the mortality rate increased to 9%.[9-14] Therefore, more and more medical personnel and scientific researchers have participated in the frontier of VTE in children with sound research results, including prevalence, etiology and pathogenesis, diagnosis, prevention and control, drug treatment, thrombolytic therapy, and complications on VTE in children. These studies have made important contributions and provided meaningful guidance for the clinical decision-making of VTE in children.

Bibliometrics is a set of special research methods that quantify documents, words, authors, citations, and co-citations through mathematical and statistical techniques.[15,16] In this study, co-word analysis was used to estimate the co-occurrence, frequency of two words in the same article, then cluster analysis was carried out to reflect the relationship between the words, and then the structure and changes of the subjects or themes represented by these words were analyzed.[17] In this way, the information related to the authors, journals, journal source countries, and the major medical subject headings (MeSH) terms was traced in these articles, and the content, characteristics, internal relations and scientific structure of children’s VTE publications were summarized. This study aimed to analyze the literature published in the PubMed database on VTE in children and provided evidence and guidance in this field for researchers, clinicians, and educators.

2. Materials and methods
2.1. Search strategy
This study retrieved the literature from PubMed. Data retrieval strategy included the following contents: #1 “Pulmonary Embolism” [Majr] OR “Venous Thromboembolism” [Majr] OR VTE [Text Word] OR DVT [Text Word] OR PTE [Text Word] OR PE [Text Word] OR Venous Thromboembolism [Title/Abstract] OR Pulmonary Embolism [Title/Abstract] OR deep vein thrombosis [Title/Abstract] OR Venous thrombosis [Title/Abstract] and #2 “Child” [Majr] OR “Adolescent” [Majr] OR “Infant, Newborn” [Majr] OR “Pediatrics” [Majr] OR Child [Title/Abstract] OR Adolescent [Title/Abstract] OR Infant [Title/Abstract] OR neonatal [Title/Abstract] OR youth [Title/Abstract] OR Pediatrics [Title/Abstract] OR children [Title/Abstract], and #3 “1988/01/01” [Date-Publication]: “2019/06/18” [Date-Publication]. The scope of literature selection was limited to the clinical trial, review, meta-analysis, observational study, randomized controlled trial, systematic reviews, case reports, clinical study, and multicenter study. In addition, there was no language restriction in this study.

2.2. Data and analysis
In this study, Bibliographic Item Co-Occurrence Matrix Builder (BICOMB) developed by the department of information management and information systems (medical science) of China Medical University was used to analyze the year of publication, journal, journal source country, and the MeSH terms.[18] Due to the length of the article, only the high-frequency MeSH terms with frequency (≥15) were selected in this study.

The co-word matrix was constructed by BICOMB using the selected high-frequency MeSH terms, and the co-word matrix was imported into gCLUTO 1.0 software, a graphical cluster toolkit developed by Rasmussen and Karypis at the University of Minnesota.[19,20] Graph clustering method was used to perform the double clustering analysis on the co-word matrix, in which cosine was taken as similarity function and k2 as standard function. In order to determine the optimal number of clusters, the different number of clusters was selected to repeat graph clustering analysis.[21] The minimum average similarity between classes (ESim) and the maximum average similarity within classes (ISim) were used as optimization results. Then, the double aggregation was further visualized to generate the visual matrix and the visual hill.

CiteSpace (5.5.R2.64 bit) software was used to perform the knowledge map of co-authors to explore the core authors. In the knowledge map, the node represents the author. The size of the node reflects the number of publications, and the larger the node, the higher the number of publications. The lines between nodes represent the co-occurrence relationship between authors, and their thickness indicates the strength of co-occurrence. In addition, the centrality is an index to measure the importance of nodes in the network. If value of centrality is >0.1, there is an important position of the node in the network. The purple circle is the key marker in the knowledge map. If there is a purple circle, it means that the centrality of the node is not <0.1.[22] These indexes were used to measure and identify the importance of co-authors in this field.

3. Results
3.1. Analysis of annual publications
A total of 1779 articles on VTE in children were obtained. Table 1 and Figure 1 showed the publication trend in the past 31 years from 1988 to 2019. In general, the publication trend has increased from 1988 to 2018. There were 14 publications in 1988, and the number of publications reached 149 in 2018. In this study, PubMed was only retrieved before June in 2019, and the number of papers has reached 57 in the first half of 2019. From 1988 to 2002, no more than 36 papers were published each year, showing a slow increase generally. From 2003 to 2009, the annual publication trend continued to grow, but the number of papers was no more than 66 per year. However, from 2013 to 2018, the annual number of papers increased significantly, reaching to 149 in 2018.

3.2. Analysis of journals and journal source countries
In total, 790 academic journals have published articles on VTE in children. Among the top 11 journals (Table 2), the journal of
thrombosis research (impact factor [IF] 2018, 3.27; Q2) contributed to the largest number of publications (34 publications, 1.91%), followed by Pediatric emergency care (IF2018, 0.36, Q4; 24 publications, 1.35%), and seminars in thrombosis and hemostasis (IF2018, 1.29, Q2; 23 publications, 1.29%).

A total of 58 journal source countries have published articles on VTE in children. Among the top 15 countries (Table 3), the United States contributed to the largest number of publications (736 publications, 41.37%), followed by England (362 publications, 20.35%), and Germany (129 publications, 7.25%).

3.3. Analysis of co-authors

Table 4 and Figure 2 showed the top 10 co-authors based on the value of centrality involving VTE in children. There were 215 nodes and 510 links in the co-author map generated by CiteSpace software (Fig. 2), and Nowak-Göttl U ranked the first, followed by Goldenberg NA, Male C and Mitchell L based on the value of centrality (Table 4) and the co-author knowledge map based on the centrality (Fig. 2). None of the co-author’s centrality value is >0.1 (Table 4), and none of the nodes representing the co-authors in the co-author knowledge map is marked with a purple circle (Fig. 2). The larger the node (representing the co-author), the larger the publication. Therefore, Nowak-Göttl U and Goldenberg NA published more articles in the field of children’s VTE due to the larger nodes.

3.4. Analysis of co-word matrix and double clustering of MeSH terms

In this study, some synonyms were combined to obtain 3099 effective MeSH terms, in which 37 MeSH terms have appeared for no <15 times (Table 5). The results of double clustering of high-frequency MeSH terms were visualized to obtain the visual matrix (Fig. 3) and the visual hill (Fig. 4). In the visual matrix, the black horizontal lines separated these MeSH terms into eight categories. The figures in Table 6 were cluster number, such as 1 represented cluster 1. Combining with the results of Table 6, the similarity of Cluster 1 was the highest (ISim=0.704, ESim=0.112), indicating that the consistency of high MeSH terms was
the research on the children the similarity within the category. The visual hill also showed that number of objects and the height of the hill was proportional to curve, which represented a rough estimate of the data distribution analyzed in Table 6.

According to the top 11 journals, the journals with IF $>3.00$ contributed to $7.46\%$ (IF $>10.00$, $1.01\%$; $10.00 \geq$ IF $>5.00$, $1.01\%$; $5.00 \geq$ IF $>3.00$, $5.44\%$) of the total number of publications. Through journal partition based on Clarivate Analytics journal citation report, it is found that except 2 journals are in Q3 and Q4, the other 9 journals are in and above Q2. At present, some journals published in articles on children’s VTE are of relatively high quality, which is not difficult to find. However, publishing studies related to VTE in children in journals with high IF, such as >10, is really challenging.

The top 15 journal source countries who engaged in the field of VTE in children, contributed to 1647 publications, accounting for 92.57% of the total publications. Among them, the number of publications issued by 2 developing countries including India and China is 47 (2.64%), and except for the above 2 countries, the rest of 1600 publications are issued by developed countries, accounting for 89.93%. It indicates that the developed countries are far more involved than the developing countries in the study field of VTE in children, and there is a big gap between them. In

| Table 2 | Top 11 journals according to the number of publications related to VTE in children. |
|---------|---------------------------------------------------------------------------------|
| Rank   | Journal                                      | Country | Publications | Percent | IF 2018 | JCR partition |
| 1      | Thrombosis research                     | England | 34           | 1.91    | 3.27    | Q2           |
| 2      | Pediatric emergency care                | USA     | 26           | 1.46    | 1.12    | Q3           |
| 3      | Archives de pediatrie: organe officiel de la Societe francaise de pediatrie   | France  | 24           | 1.35    | 0.36    | Q4           |
| 4      | Seminars in thrombosis and hemostasis  | USA     | 23           | 1.29    | 3.40    | Q2           |
| 5      | The Journal of pediatrics               | USA     | 22           | 1.23    | 3.74    | Q1           |
| 6      | Pediatric blood and cancer              | USA     | 22           | 1.23    | 2.49    | Q1           |
| 7      | Journal of pediatric surgery            | USA     | 19           | 1.07    | 2.09    | Q2           |
| 8      | Blood                                  | USA     | 18           | 1.01    | 16.56   | Q1           |
| 9      | Pediatric nephrology                    | Germany | 18           | 1.01    | 2.82    | Q1           |
| 10     | Journal of thrombosis and haemostasis: JTH | USA   | 18           | 1.01    | 4.66    | Q1           |
| 11     | Journal of pediatric hematology/oncology| England | 18           | 1.01    | 8.73    | Q1           |

| Table 3 | Top 15 journal source countries according to the number of publications related to VTE in children. |
|---------|-------------------------------------------------------------------------------------------------|
| Rank   | Country             | Publications | Percent | Cumulative percent |
| 1      | United States       | 736          | 41.37   | 41.37             |
| 2      | England             | 362          | 20.35   | 61.72             |
| 3      | Germany             | 129          | 7.25    | 68.97             |
| 4      | France              | 92           | 5.17    | 74.14             |
| 5      | Switzerland         | 70           | 3.93    | 78.07             |
| 6      | Netherlands         | 61           | 3.43    | 81.50             |
| 7      | Italy               | 33           | 1.86    | 83.36             |
| 8      | India               | 32           | 1.89    | 85.16             |
| 9      | Australia           | 28           | 1.57    | 86.73             |
| 10     | Spain               | 24           | 1.35    | 88.08             |
| 11     | Japan               | 21           | 1.18    | 89.26             |
| 12     | Denmark             | 18           | 1.01    | 90.27             |
| 13     | China               | 15           | 0.84    | 91.11             |
| 14     | New Zealand         | 14           | 0.79    | 91.90             |
| 15     | Ireland             | 12           | 0.67    | 92.57             |

| Table 4 | Top 10 co-authors according to centrality related to VTE in children. |
|---------|---------------------------------------------------------------------|
| Rank   | Co-authors | Centrality | Country |
| 1      | Nowak-Göttl U | 0.04     | Germany |
| 2      | Goldenberg NA  | 0.03     | USA     |
| 3      | Male C        | 0.03     | Germany |
| 4      | Mitchell L    | 0.03     | Canada  |
| 5      | Kenet G       | 0.02     | Israel  |
| 6      | Andrew M      | 0.02     | Canada  |
| 7      | Marzinotto V  | 0.02     | Canada  |
| 8      | van Ommen CH  | 0.01     | Netherlands |
| 9      | Waren P       | 0.01     | USA     |
| 10     | Tarango C     | 0.01     | USA     |

College of Chest Physicians (ACCP) guidelines on children’s VTE treatment in 1995 and 2012,\textsuperscript{22} which stimulated the increase of papers in the field of VTE in children to some extent. Besides, American Society of Hematology 2018 Guidelines for management of VTE: treatment of pediatric VTE\textsuperscript{22} has been issued, which may further stimulate the in-depth and extensive research in the field of VTE in children in the future. In addition, an increase in the number of indexed journals in the PubMed database may also lead to an increase in the number of publications. Although the annual research volume of children’s VTE is increasing, it should be noted that the overall research progress in this field is still slow.\textsuperscript{23}

According to the top 11 journals, the journals with IF $>3.00$ contributed to $7.46\%$ (IF $>10.00$, $1.01\%$; $10.00 \geq$ IF $>5.00$, $1.01\%$; $5.00 \geq$ IF $>3.00$, $5.44\%$) of the total number of publications. Through journal partition based on Clarivate Analytics journal citation report, it is found that except 2 journals are in Q3 and Q4, the other 9 journals are in and above Q2. At present, some journals published in articles on children’s VTE are of relatively high quality, which is not difficult to find. However, publishing studies related to VTE in children in journals with high IF, such as >10, is really challenging.

The top 15 journal source countries who engaged in the field of VTE in children, contributed to 1647 publications, accounting for 92.57% of the total publications. Among them, the number of publications issued by 2 developing countries including India and China is 47 (2.64%), and except for the above 2 countries, the rest of 1600 publications are issued by developed countries, accounting for 89.93%. It indicates that the developed countries are far more involved than the developing countries in the study field of VTE in children, and there is a big gap between them. In
Figure 2. Map of co-authors performing studies related to VTE in children.

| Rank | Major MeSH terms                                      | Frequency | Percent | Cumulative percent |
|------|------------------------------------------------------|-----------|---------|--------------------|
| 1    | Venous thromboembolism/etiology                     | 149       | 2.42    | 2.42               |
| 2    | Venous thromboembolism/diagnosis                    | 110       | 1.78    | 4.20               |
| 3    | Anticoagulants/therapeutic use                       | 79        | 1.28    | 5.48               |
| 4    | Pulmonary embolism/etiology                         | 75        | 1.22    | 6.70               |
| 5    | Venous thromboembolism/epidemiology                 | 73        | 1.18    | 7.88               |
| 6    | Venous thromboembolism/prevention and control       | 68        | 1.10    | 8.98               |
| 7    | Pulmonary embolism/diagnosis                        | 59        | 0.96    | 9.94               |
| 8    | Pulmonary embolism/diagnosis                        | 51        | 0.83    | 10.77              |
| 9    | Venous thromboembolism/comlications                 | 49        | 0.79    | 11.56              |
| 10   | Venous Thromboembolism / therapy                    | 41        | 0.66    | 12.22              |
| 11   | Catheterization, central venous/adverse effects     | 38        | 0.62    | 12.84              |
| 12   | Pulmonary embolism/comlications                      | 34        | 0.55    | 13.39              |
| 13   | Venous thromboembolism/genetics                     | 33        | 0.53    | 13.92              |
| 14   | Pulmonary embolism/diagnostic imaging               | 32        | 0.52    | 14.44              |
| 15   | Anticoagulants/therapeutic use                       | 31        | 0.50    | 14.94              |
| 16   | Factor V/Genetics                                   | 29        | 0.47    | 15.41              |
| 17   | Pulmonary embolism/drug therapy                     | 28        | 0.45    | 15.86              |
| 18   | Heparin, low-molecular-weight/therapeutic use        | 22        | 0.36    | 16.22              |
| 19   | Anticoagulants/administration and dosage             | 22        | 0.36    | 16.58              |
| 20   | Intracranial thrombosis/etiology                    | 21        | 0.34    | 16.92              |
| 21   | Venous thromboembolism/diagnostic imaging           | 21        | 0.34    | 17.26              |
| 22   | Sinus thrombosis, intracranial/etiology             | 20        | 0.32    | 17.58              |
| 23   | Thrombolytic therapy/methods                        | 19        | 0.31    | 17.89              |
| 24   | Staphylococcal infections/complications              | 19        | 0.31    | 18.20              |
| 25   | Pulmonary embolism/surgery                          | 18        | 0.29    | 18.49              |
| 26   | Plasma exchange                                     | 18        | 0.29    | 18.78              |
| 27   | Tissue plasminogen Activator / therapeutic use       | 18        | 0.29    | 19.07              |
| 28   | Thrombophilia/complications                          | 17        | 0.28    | 19.35              |
| 29   | Antithrombin-1 syndrome/complications                | 17        | 0.28    | 19.63              |
| 30   | Prothrombin/genetics                                | 17        | 0.28    | 19.91              |
| 31   | Heparin/therapeutic use                              | 17        | 0.28    | 20.19              |
| 32   | Pulmonary embolism/pathology                        | 17        | 0.28    | 20.47              |
| 33   | Venous thromboembolism/pathology                    | 16        | 0.26    | 20.73              |
| 34   | Thrombophilia/genetics                              | 16        | 0.26    | 20.99              |
| 35   | Nephrotic syndrome/complications                     | 15        | 0.24    | 21.23              |
| 36   | Venous thromboembolism/pathology                    | 15        | 0.24    | 21.47              |
| 37   | Mutation                                            | 15        | 0.24    | 21.71              |

MeSH = major medical subject headings.
the future, developing countries need to increase their research efforts to facilitate the international research exchanges in order to enhance its international influence in the field of children VTE. Moreover, the number of publications issued by 3 Asian countries including China, India, and Japan is 68 (3.88%); the number of publications issued by 9 Europe countries including England, Germany, France, Switzerland, Netherlands, Italy, Spain, Denmark, and Ireland is 585 (46.82%); the number of publications issued by 2 Oceania countries including Australia and New Zealand is 42 (2.36%) and by 1 North America country, namely the United States, is 736 (41.37%). It has been reported that DVT and PE are considered rare in Asian population compared with Caucasians.[24] The above results illustrate that the United States, which accounts for almost one-half of the total publications, has proved to be a major force in this field. To sum up, there are two reasons for the research gap of VTE incidence in children:
1. the difference of regional incidence of VTE; and
2. the higher the level of national scientific research, the more the related journals with the more international influence.

Therefore, more academic resources should be promoted for developed countries and the United States to do relevant research in the field of VTE in children, and more opportunities should be established to publish and display these research results.

Through knowledge map, information about potential collaborators was obtained to seek cooperation with other researchers. As a co-author, Nowak-Göttl U who is from Germany and mainly engaged in the research of incidence, influencing factors, prevention and treatment, etiology on VTE in children, ranked the first with the centrality value of 0.04. Even though her centrality result is <0.1, it is still believed that she is an active and professional researcher in this field, owing to the close cooperation between research teams centered on her. In other words, she is the core member of influential research teams. In addition, it is found that none of the centrality value >0.1, indicating that many authors did not collaborate closely in this field. The lack of communication and cooperation is not conducive to promoting researchers’ mutual learning and progress in the field of VTE in children.

In this study, eight clusters were obtained by means of double clustering analysis of co-word matrix of high-frequency MeSH terms (≥15). Based on the clustering results, the following research hotspots were summarized in this field:

4.1. Inherited thrombophilia study of VTE in children based on cluster 2.

Inherited thrombophilia (IT) refers to the tendency of VTE in the case of hypercoagulability caused by genetic traits, such as
mutations of factor 2 (F2: rs1799963) and factor 5 (F5: rs6025), and the deficiency of antithrombin, protein S, and protein C.[25,26] The studies mainly concentrated on the following two points: the impact of IT on the formation of VTE in children; can children with VTE or offspring of thrombophilic families benefit from IT testing? Studies have shown that IT plays an important role in VTE in children. With the occurrence of more than two genetic traits, the risk of VTE is further increased; however, the extent of this effect may be affected by specific pediatric subgroups (e.g., first episode and recurrent VTE, induced and non-induced VTE), in which other risk factors may play a more important role, such as the presence of central venous catheter (CVC) or potential medical conditions.[27-29] Studies have shown that IT test should be performed in patients with non-induced VTE, recurrent VTE, and those with a strong family history of VTE. However, the benefits of IT test are less clear for other pediatric patients.[28]

4.2. Prevention and control study of VTE in children based on cluster 3

Studies have shown that early activity,[30] mechanical prevention including intermittent pneumatic compression (IPC) and graduated compression stockings, and pharmacologic prophylaxis are the main prevention strategies for VTE in children.[9] For the pharmacologic prophylaxis, even recommendations for therapeutic ranges are low molecular weight heparin (LMWH) anti-Xa 0.1 to 0.3 U/mL or warfarin INR 1.3 to 1.9 from the 2012 Chest guidelines.[131] There are still limited studies on the efficacy and safety of anticoagulants in preventing VTE in pediatric patients. Preventive LMWH is reported to have a risk of bleeding of 0.8% in massive bleeding and 3% in minor bleeding.[12] Therefore, in order to effectively balance the risks and benefits of preventive measures, the risk assessment model (RAM) is suggested to be used to stratify VTE risks.[133]

4.3. Treatment study of VTE in children based on clusters 0 and 1

Early identification and diagnosis of VTE can ensure timely treatment and adequate anticoagulation to reduce the harms associated with VTE. The purpose of anticoagulation is to prevent clot proliferation and embolism, maintain vascular access, and prevent bacteremia.[134] The most commonly used treatment for DVT in children is LMWH, which provides several potential benefits, including fewer changes by other concurrent drugs, predictable pharmacokinetics and minimal monitoring comparing with heparin and warfarin.[31,35] Thrombolysis which is given systemically or via a catheter-directed approach is a more aggressive treatment for the management of DVT.[136] High- and low-dose systemic thrombolytic regimens have been established in children, usually with anticoagulation and close monitoring of bleeding at the same time.[157,138] Tissue plasminogen activator (alteplase) is a major thrombolytic agent for thrombolysis, and study have showed that thrombolysis is more effective in preventing PTS than in anticoagulation.[139]

4.4. Diagnosis study of VTE in children based on clusters 4 and 5

It mainly involves laboratory and imaging diagnosis research. In laboratory diagnosis, a lot of researches have been performed on d-dimer, and study have indicated that d-dimer has not been proven to diagnose VTE in pediatric clinical trials, but a recurrence risk.[140] When VTE is suspected, the imaging method is chosen depending on the location of the thrombosis.
Historically, venography has been the gold standard, which is very useful in assessing limbs or thoracoabdominal areas. Recently, magnetic resonance venography (MRV) and computed tomography venography have replaced traditional venography as the main imaging tool for abdomen and chest. In addition, MRV is the preferred method for the diagnosis of cerebral sinus venous thrombosis.[36]

4.5. Prevalence, risk factors, and complication study of VTE in children based on clusters 3, 4, 6, and 7

At present, although many studies around the world have reported the incidence of children’s VTE, there is still no consensus on the prevalence of children’s VTE. The results of children’s VTE incidence vary greatly from 0.00% to 77.78%.[41,42] owing to the different research subjects, design, sample size, and data collection time in each study. Risk factors for VTE in children include multiple genetic and acquired factors. Acquired factors mainly include certain diseases, their corresponding treatments and individual risk factors. Risk factors associated with the disease include premature delivery, inflammatory diseases, trauma (especially severe trauma of lower limb or pelvic fractures), cancer diagnosis, dehydration, poor perfusion, decreased mobility, and severe infection.[33] Treatment-related risk factors include CVAD (which is considered as the most important risk factor), intensive careunit (ICU) admission, surgery, parenteral nutrition, chemotherapy (such as steroid or asparaginase use), length of stay (LOS), blood transfusion, intubation, mechanical ventilation, estrogen-containing hormone therapy (such as oral contraceptives), and inotropic support.[33,44] Individual risk factors include age and obesity.[31] PTS is the most common complication of VTE. At present, the reported results of the incidence of children’s PTS are quite different.[44,45] The incidence of children’s PTS varies from 10% to 60%, mainly depending on the different tools for the incidence assessment of PTS.[46] The modified Villalta (MV) score and the Manco Johnson Instrument (MJI) are the two most commonly used tools.[47] It should be noted that the differences of scores given by different tools are mainly attributed to subjective symptoms rather than objective signs.[22]

However, our study still has some limitations. First, PubMed was chosen as the only data source in this study, and there may be limitations in the research results. Therefore, in the follow-up research, retrieval method should be adopted in multi-database to avoid the data limitation. Moreover, the inclusion and exclusion criteria of literature are not strictly given in this study. If bibliometrics and co-word analysis include reviews and clinical trial articles, these materials may contain repetitive studies. If reviewing articles are excluded and clinical trials are only included, some research hotspots may be lost. These limitations need to be addressed and improved in future studies.

5. Conclusion

In this study, the development trend of children’s VTE in recent 31 years is summarized and analyzed to illustrate the research hotspots of this field. It is found that the research trend of children’s VTE has been increasing gradually, indicating that the problem of VTE in children has aroused the concern. The research results in these hotspots were obtained regarding the area of IT, prevention and control, treatment, diagnosis, prevalence, risk factors, and complication study of VTE in children. However, communication and cooperation in this field is lacked with the huge gap of national and regional research.

Author contributions

Conceptualization: Lingyun Tian, Yinglan Li.
Data curation: Lingyun Tian, Ying Zhang, Jiaqi Zeng.
Formal analysis: Lingyun Tian, Liqian Wang, Huimin Gao, Yanan Su, Yinglan Li.
Investigation: Lingyun Tian, Ying Zhang.
Methodology: Lingyun Tian, Ying Zhang, Jiaqi Zeng, Liqian Wang, Huimin Gao, Yanan Su, Yinglan Li.
Software: Lingyun Tian, Ying Zhang, Jiaqi Zeng.
Supervision: Lingyun Tian, Yinglan Li.
Visualization: Lingyun Tian, Ying Zhang.
Writing – original draft: Lingyun Tian.
Writing – review & editing: Lingyun Tian, Ying Zhang, Jiaqi Zeng, Liqian Wang, Huimin Gao, Yanan Su, Yinglan Li.

References

[1] Mahajaran A, Betensky M, Goldenberg NA. Thrombosis in children: approach to anatomic risks, thrombophilia, prevention, and treatment. Hematol Oncol Clin North Am 2019;33:439–53.
[2] Rafiei L, Huang YS, Witting C, et al. Dramatic increase in venous thromboembolism in children’s hospitals in the United States from 2001 to 2007. Pediatrics 2009;124:1001–8.
[3] Biss TT. Venous thromboembolism in children: is it preventable? Semin Thromb Hemost 2016;42:603–11.
[4] Kenet G, Limperger V, Shneyder M, et al. Risk factors for symptomatic venous and arterial thromboembolism in newborns, children and adolescents—what did we learn within the last 20 years? Blood Cells Mol Dis 2017;67:18–22.
[5] Chopra V, Anand S, Hickner A, et al. Risk of venous thromboembolism associated with peripherally inserted central catheters: a systematic review and meta-analysis. Lancet 2013;382:311–25.
[6] Boulet SL, Amendah D, Groose SD, et al. Health care expenditures associated with venous thromboembolism among children. Thromb Res 2012;129:583–7.
[7] Branchford BR. Clinical and financial impact of HACs: a commentary on clinical and financial costs of hospital-acquired conditions. Transl Pediatr 2015;4:331–3.
[8] Goudie A, Dynean L, Brady PW, et al. Costs of venous thromboembolism, catheter-associated urinary tract infection, and pressure ulcer. Pediatrics 2015;136:432–9.
[9] Morgan J, Cheekets M, Arana A, et al. Prevention of perioperative venous thromboembolism in pediatric patients: guidelines from the Association of Paediatric Anaesthetists of Great Britain and Ireland (APAGBI). Paediatr Anaesth 2018;28:382–91.
[10] Branchford BR, Mourani P, Bajaj L, et al. Risk factors for in-hospital venous thromboembolism in children: a case-control study employing diagnostic validation. Haematologica 2012;97:509–15.
[11] Meier KA, Clark E, Tarango C, et al. Venous thromboembolism in hospitalized adolescents: an approach to risk assessment and prophylaxis. Hosp Pediatr 2015;5:444–51.
[12] Kuhle S, Koloshuk B, Marzioni V, et al. A cross-sectional study evaluating post-thrombotic syndrome in children. Thromb Res 2003;112:227–33.
[13] Goldenberg NA, Donadini MP, Kahn SR, et al. Post-thrombotic syndrome in children: a systematic review of frequency of occurrence, validity of outcome measures, and prognostic factors. Haematologica 2010;95:1952–9.
[14] Avila ML, Duan L, Cipolla A, et al. Postthrombotic syndrome following upper extremity deep vein thrombosis in children. Blood 2014;124:1166–73.
[15] Gang KC, Kumar S, Madhavi Y, et al. Bibliometrics of global malaria vaccine research. Health Info Libr J 2009;26:22–31.
[16] Estabrooks CA, Winther C, Derksen L. Mapping the field: a bibliometric analysis of the research utilization literature in nursing. Nurs Res 2004;53:293–303.
[17] Zhang XC, Huang DS, Li F. Cancer nursing research output and topics in the first decade of the 21st century: results of a bibliometric and co-word cluster analysis. Asian Pac J Cancer Prev 2011;12:2055–8.
[18] Cui L, Liu W, Yan L, et al. Development of bibliographic information co-occurrence mining system in document database. New Technol Library Inform Serv 2008;70–5.
[19] Rasmussen M, Karspis G. gCluto: an interactive clustering, visualization, and analysis system. http://glaros.dtc.umn.edu/gkhome/cluto/gcluto/publications Accessed June 10, 2019
[20] Wang L. Application of Biclustering on classification of scientific researchers based on literature profiling. Shenyang, China: Chinese Medical Sciences University; 2012.
[21] Chen C. CiteSpace II: detecting and visualizing emerging trends and transient patterns in scientific literature. J Assoc Inform Sci Technol 2014;57:359–77.
[22] Monagle P. Slow progress. How do we shift the paradigm of thinking in pediatric thrombosis and anticoagulation? Thromb Res 2019;173:186–90.
[23] Monagle P, Caello CA, Augustine C, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: treatment of pediatric venous thromboembolism. Blood Adv 2018;2:3292–316.
[24] Law Y, Chan YC, Cheng SWK. Epidemiological updates of venous thromboembolism in a Chinese population. Asian J Surg 2018;41:176–82.
[25] Nowak-Göttl U, van Ommen H, Kenet G. Thrombophilia testing in children: what and when should be tested? Thromb Res 2018;164:75–82.
[26] Young G, Albusetti M, Bonduel M, et al. Impact of inherited thrombophilia on venous thromboembolism in children: a systematic review and meta-analysis of observational studies. Circulation 2008;118:1373–82.
[27] Kenet G, Luskoff LK, Albusetti M, et al. Impact of thrombophilia on risk of arterial ischemic stroke or cerebral sinus venous thrombosis in neonates and children: a systematic review and meta-analysis of observational studies. Circulation 2010;121:1838–47.
[28] Kreuz W, Stoll M, Junker R, et al. Familial elevated factor VIII in children with symptomatic venous thrombosis and post-thrombotic syndrome: results of a multicenter study. Arterioscler Thromb Vasc Biol 2006;26:1901–6.
[29] Ishola T, Kirk SE, Guffey D, et al. Risk factors and co-morbidities in adolescent thromboembolism are different than those in younger children. Thromb Res 2016;141:178–82.
[30] Wittmer CM, Takemoto CM. Pediatric hospital acquired venous thromboembolism. Front Pediatr 2017;5:198.
[31] Monagle P, Chan AKC, Goldenberg NA, et al. Antithrombotic therapy in neonates and children: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Chest 2012;141(2 Suppl):e737S–S41.
[32] Nowak-Göttl U, Riedlingmaier C, Krümpel A, et al. Pharmacokinetics, efficacy, and safety of LMWHs in venous thrombosis and stroke in neonates, infants and children. Br J Pharmacol 2008;153:1120–7.
[33] Rühle F, Stoll M. Advances in predicting venous thromboembolism risk in children. Br J Haematol 2018;180:65–6.
[34] Massicotte P, Julian JA, Gent M, et al. An open-label randomized controlled trial of low molecular weight heparin for the prevention of central venous line-related thrombotic complications in children: the PROTEKT trial. Thromb Res 2003;109:101–8.
[35] Massicotte P, Julian JA, Gent M, et al. An open-label randomized controlled trial of low molecular weight heparin compared to heparin and Coumadin for the treatment of venous thromboembolic events in children: the REVIVE trial. Thromb Res 2003;109:85–92.
[36] Jaffray J, Young G. Deep vein thrombosis in pediatric patients. Pediatr Blood Cancer 2018;65:e26881.
[37] Manco-Johnson MJ, Nuss R, Hays T, et al. Combined thrombolytic and anticoagulant therapy for venous thrombosis in children. J Pediatr 2000;136:446–53.
[38] Wang M, Hays T, Balasa V, et al. Low-dose tissue plasminogen activator thrombolysis in children. J Pediatr Hematol Oncol 2003;25:379–86.
[39] Goldenberg NA, Durham JD, Knapp-Clevenger R, et al. A thrombolytic regimen for high-risk deep venous thrombosis may substantially reduce the risk of postthrombotic syndrome in children. Blood 2007;110:45–53.
[40] Goldenberg NA, Knapp-Clevenger R, Manco-Johnson MJ, et al. Elevated plasma factor VIII and D-dimer levels as predictors of poor outcomes of thrombosis in children. N Engl J Med 2004;351:1081–8.
[41] Scherer AG, White IK, Shaikh KA, et al. Risk of deep venous thrombosis in elective neurosurgical procedures: a prospective, Doppler ultrasound-based study in children 12 years of age or younger. J Neurosurg Pediatr 2017;20:71–6.
[42] Goldenberg NA, Knapp-Clevenger R, Hays T, et al. Lemierre’s and Lemierre’s-like syndromes in children: survival and thromboembolic outcomes. Pediatrics 2005;116:e543–8.
[43] Landisch RM, Hansson SJ, Cassidy LD, et al. Evaluation of guidelines for injured children at high risk for venous thromboembolism: a prospective observational study. J Trauma Acute Care Surg 2017;82:836–44.
[44] Revel-Vilk S, Brândiu LR, Journeycake J, et al. Standardization of post-thrombotic syndrome definition and outcome assessment following upper venous system thrombosis in pediatric practice. J Thromb Haemost 2012;10:2182–5.
[45] Goldenberg NA, Brândiu L, Journeycake J, et al. Definition of post-thrombotic syndrome following lower extremity deep venous thrombosis and standardization of outcome measurement in pediatric clinical investigations. J Thromb Haemost 2012;10:477–80.
[46] Jones S, Newall F, Monagle P. Novel perspectives on diagnosis and clinical significance of the post-thrombotic syndrome in children. Expert Rev Hematol 2016;9:965–75.
[47] Polen E, Weintraub M, Stoffer C, et al. Post-thrombotic syndrome after central venous catheter removal in childhood cancer survivors: a prospective cohort study. Pediatr Blood Cancer 2015;62:285–90.